demonstrated that 90% (9/10) of patients with breast ductal carcinoma in situ with HER2-positive subtypes demonstrated a clinical response to the 6 HER2/neu MHC class II promiscuous-binding peptide-pulsed DC vaccine, accompanied by a decline and/or eradication of HER2/neu expression in some patients (31). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.